Liminatus Pharma (LIMN) Competitors $5.45 -0.02 (-0.37%) As of 03:32 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock LIMN vs. RAPP, ORKA, ARVN, KURA, VALN, TSHA, PRME, PGEN, ATAI, and BCYCShould you be buying Liminatus Pharma stock or one of its competitors? The main competitors of Liminatus Pharma include Rapport Therapeutics (RAPP), Oruka Therapeutics (ORKA), Arvinas (ARVN), Kura Oncology (KURA), Valneva (VALN), Taysha Gene Therapies (TSHA), Prime Medicine (PRME), Precigen (PGEN), atai Life Sciences (ATAI), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Liminatus Pharma vs. Its Competitors Rapport Therapeutics Oruka Therapeutics Arvinas Kura Oncology Valneva Taysha Gene Therapies Prime Medicine Precigen atai Life Sciences Bicycle Therapeutics Liminatus Pharma (NASDAQ:LIMN) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends. Which has higher valuation and earnings, LIMN or RAPP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLiminatus PharmaN/AN/AN/AN/AN/ARapport TherapeuticsN/AN/A-$78.31M-$3.45-4.33 Do analysts prefer LIMN or RAPP? Rapport Therapeutics has a consensus target price of $28.00, indicating a potential upside of 87.23%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapport Therapeutics is more favorable than Liminatus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LIMN or RAPP more profitable? Liminatus Pharma's return on equity of 0.00% beat Rapport Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Liminatus PharmaN/A N/A N/A Rapport Therapeutics N/A -25.48%-24.63% Does the media favor LIMN or RAPP? In the previous week, Rapport Therapeutics had 3 more articles in the media than Liminatus Pharma. MarketBeat recorded 4 mentions for Rapport Therapeutics and 1 mentions for Liminatus Pharma. Rapport Therapeutics' average media sentiment score of 0.09 beat Liminatus Pharma's score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liminatus Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapport Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryRapport Therapeutics beats Liminatus Pharma on 5 of the 7 factors compared between the two stocks. Get Liminatus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIMN vs. The Competition Export to ExcelMetricLiminatus PharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$140.97M$232.31M$2.18B$9.40BDividend YieldN/AN/A2.60%4.05%P/E RatioN/AN/A22.2719.83Price / SalesN/AN/A96.02100.57Price / CashN/AN/A13.4057.94Price / BookN/AN/A73.075.64Net IncomeN/AN/A-$127.36M$257.88M7 Day Performance-18.50%-13.59%1.04%2.00%1 Month PerformanceN/A935.51%2.31%11.05%1 Year PerformanceN/A141.66%22.01%18.37% Liminatus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIMNLiminatus PharmaN/A$5.45-0.4%N/AN/A$141.75MN/A0.00N/AGap UpRAPPRapport Therapeutics1.4159 of 5 stars$15.22+5.8%$28.00+84.0%-43.3%$555.53MN/A-4.41N/AInsider TradeORKAOruka Therapeutics2.9736 of 5 stars$14.80+3.9%$40.38+172.8%N/A$554.13MN/A-3.28N/ANews CoveragePositive NewsARVNArvinas3.9297 of 5 stars$7.59+2.6%$20.29+167.3%-75.1%$554.00M$426.90M-11.50420KURAKura Oncology4.5735 of 5 stars$6.38+4.1%$24.50+284.0%-69.6%$552.35M$67.99M-3.04130Positive NewsVALNValneva1.8243 of 5 stars$6.49+0.6%$15.50+138.8%-16.6%$552.23M$183.52M-5.45700TSHATaysha Gene Therapies4.0333 of 5 stars$2.54+1.2%$8.17+221.5%+13.1%$545.24M$7.22M-7.47180PRMEPrime Medicine3.8264 of 5 stars$4.04-5.8%$10.08+149.6%-38.0%$543.36M$3.85M-1.97234News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumePGENPrecigen4.0694 of 5 stars$1.84-0.5%$6.00+226.1%+5.2%$543.13M$3.92M-3.29190Positive NewsAnalyst RevisionATAIatai Life Sciences3.2147 of 5 stars$2.70+1.9%$9.00+233.3%+74.4%$540.92M$310K-2.9780BCYCBicycle Therapeutics3.7251 of 5 stars$7.78+1.3%$25.00+221.3%-65.6%$538.80M$25.72M-2.48240News CoverageAnalyst Forecast Related Companies and Tools Related Companies Rapport Therapeutics Competitors Oruka Therapeutics Competitors Arvinas Competitors Kura Oncology Competitors Valneva Competitors Taysha Gene Therapies Competitors Prime Medicine Competitors Precigen Competitors atai Life Sciences Competitors Bicycle Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIMN) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMissed the Run So Far? This Is Your Second ChanceAccording to history, the final stretch of the crypto cycle is here — and this short window is where fortunes ...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
